Xbrane Biopharma AB (STU:7XB) LT-Debt-to-Total-Asset : 0.15 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Xbrane Biopharma AB's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.15.

Xbrane Biopharma AB's long-term debt to total assets ratio increased from Mar. 2023 (0.05) to Mar. 2024 (0.15). It may suggest that Xbrane Biopharma AB is progressively becoming more dependent on debt to grow their business.

Xbrane Biopharma AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Xbrane Biopharma AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB LT-Debt-to-Total-Asset Chart

Xbrane Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

0.05

0.04

0.24

Xbrane Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.17	0.19	0.24	0.15

Xbrane Biopharma AB LT-Debt-to-Total-Asset Calculation

Xbrane Biopharma AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	13.911	/	58.422
	=	0.24

Xbrane Biopharma AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	11.871	/	79.41
	=	0.15

Xbrane Biopharma AB (STU:7XB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Xbrane Biopharma AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Xbrane Biopharma AB (STU:7XB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

XBRANE:Sweden 7XB:Germany

Address

Retzius vag 8, Solna, SWE, 171 65

Website

https://www.xbrane.com

Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines